The potential economic value of a Staphylococcus aureus vaccine for neonates

Bruce Y. Lee; Paul J. Ufberg; Rachel R. Bailey; Ann E. Wiringa; Kenneth J. Smith; Andrew J. Nowalk; Conor Higgins; Angela R. Wateska; Robert R. Muder

doi:10.1016/j.vaccine.2010.04.069

The potential economic value of a Staphylococcus aureus vaccine for neonates

Bruce Y. Lee, Paul J. Ufberg, Rachel R. Bailey, Ann E. Wiringa, Kenneth J. Smith, Andrew J. Nowalk, Conor Higgins, Angela R. Wateska, Robert R. Muder

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

The continuing morbidity and mortality associated with Staphylococcus aureus (S. aureus) infections, especially methicillin-resistant S. aureus (MRSA) infections, have motivated calls to make S. aureus vaccine development a research priority. We developed a decision analytic computer simulation model to determine the potential economic impact of a S. aureus vaccine for neonates. Our results suggest that a S. aureus vaccine for the neonatal population would be strongly cost-effective (and in many situations dominant) over a wide range of vaccine efficacies (down to 10%) for vaccine costs (≤$500), and S. aureus attack rates (≥1%).

Original language	English (US)
Pages (from-to)	4653-4660
Number of pages	8
Journal	Vaccine
Volume	28
Issue number	29
DOIs	https://doi.org/10.1016/j.vaccine.2010.04.069
State	Published - Jun 23 2010
Externally published	Yes

Keywords

Economics
Staphylococcus aureus
Vaccine

ASJC Scopus subject areas

Molecular Medicine
Immunology and Microbiology(all)
veterinary(all)
Public Health, Environmental and Occupational Health
Infectious Diseases

Access to Document

10.1016/j.vaccine.2010.04.069

Cite this

@article{1da2f451f81b4db2926a78d19d6e373a,

title = "The potential economic value of a Staphylococcus aureus vaccine for neonates",

abstract = "The continuing morbidity and mortality associated with Staphylococcus aureus (S. aureus) infections, especially methicillin-resistant S. aureus (MRSA) infections, have motivated calls to make S. aureus vaccine development a research priority. We developed a decision analytic computer simulation model to determine the potential economic impact of a S. aureus vaccine for neonates. Our results suggest that a S. aureus vaccine for the neonatal population would be strongly cost-effective (and in many situations dominant) over a wide range of vaccine efficacies (down to 10%) for vaccine costs (≤$500), and S. aureus attack rates (≥1%).",

keywords = "Economics, Staphylococcus aureus, Vaccine",

author = "Lee, {Bruce Y.} and Ufberg, {Paul J.} and Bailey, {Rachel R.} and Wiringa, {Ann E.} and Smith, {Kenneth J.} and Nowalk, {Andrew J.} and Conor Higgins and Wateska, {Angela R.} and Muder, {Robert R.}",

note = "Funding Information: Supported by the National Institute of General Medical Sciences Models of Infectious Disease Agent Study (MIDAS) through grant 1U54GM088491-0109 , the Pennsylvania Department of Health, and the Vaccine Modeling Initiative (VMI), funded by the Bill and Melinda Gates Foundation. The funder had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. ",

year = "2010",

month = jun,

day = "23",

doi = "10.1016/j.vaccine.2010.04.069",

language = "English (US)",

volume = "28",

pages = "4653--4660",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "29",

}

TY - JOUR

T1 - The potential economic value of a Staphylococcus aureus vaccine for neonates

AU - Lee, Bruce Y.

AU - Ufberg, Paul J.

AU - Bailey, Rachel R.

AU - Wiringa, Ann E.

AU - Smith, Kenneth J.

AU - Nowalk, Andrew J.

AU - Higgins, Conor

AU - Wateska, Angela R.

AU - Muder, Robert R.

N1 - Funding Information: Supported by the National Institute of General Medical Sciences Models of Infectious Disease Agent Study (MIDAS) through grant 1U54GM088491-0109 , the Pennsylvania Department of Health, and the Vaccine Modeling Initiative (VMI), funded by the Bill and Melinda Gates Foundation. The funder had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

PY - 2010/6/23

Y1 - 2010/6/23

N2 - The continuing morbidity and mortality associated with Staphylococcus aureus (S. aureus) infections, especially methicillin-resistant S. aureus (MRSA) infections, have motivated calls to make S. aureus vaccine development a research priority. We developed a decision analytic computer simulation model to determine the potential economic impact of a S. aureus vaccine for neonates. Our results suggest that a S. aureus vaccine for the neonatal population would be strongly cost-effective (and in many situations dominant) over a wide range of vaccine efficacies (down to 10%) for vaccine costs (≤$500), and S. aureus attack rates (≥1%).

AB - The continuing morbidity and mortality associated with Staphylococcus aureus (S. aureus) infections, especially methicillin-resistant S. aureus (MRSA) infections, have motivated calls to make S. aureus vaccine development a research priority. We developed a decision analytic computer simulation model to determine the potential economic impact of a S. aureus vaccine for neonates. Our results suggest that a S. aureus vaccine for the neonatal population would be strongly cost-effective (and in many situations dominant) over a wide range of vaccine efficacies (down to 10%) for vaccine costs (≤$500), and S. aureus attack rates (≥1%).

KW - Economics

KW - Staphylococcus aureus

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=77953123120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953123120&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2010.04.069

DO - 10.1016/j.vaccine.2010.04.069

M3 - Article

C2 - 20472028

AN - SCOPUS:77953123120

SN - 0264-410X

VL - 28

SP - 4653

EP - 4660

JO - Vaccine

JF - Vaccine

IS - 29

ER -

The potential economic value of a Staphylococcus aureus vaccine for neonates

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this